Beta-Blockers in the Prevention and Treatment of Ischemic Heart Disease: Evidence and Clinical Practice

Heart Views. 2023 Jan-Mar;24(1):41-49. doi: 10.4103/heartviews.heartviews_75_22. Epub 2023 Feb 23.

Abstract

Coronary artery disease (CAD) is the most prevalent cardiovascular disease characterized by atherosclerotic plaque buildup that can lead to partial or full obstruction of blood flow in the coronary arteries. Treatment for CAD involves a combination of lifestyle changes, pharmacologic therapy, and modern revascularization procedures. Beta-adrenoceptor antagonists (or beta-blockers) have been widely used for decades as a key therapy for CAD. In this review, prior studies are examined to better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting. The evidence for the benefit of beta-blocker therapy is well established for patients with acute myocardial infarction, but it diminishes as the time from the index cardiac event elapses. The evidence for benefit in the perioperative setting is not strong.

Keywords: Acute coronary syndrome; beta-blocker; coronary artery disease.

Publication types

  • Review